Latent TB Infection (LTBI) - Mycobacterium tuberculosis pathogenesis and the dynamics of the granuloma battleground

Latent tuberculosis infection (LTBI) is established in over 90% of persons infected with Mycobacterium tuberculosis (Mtb), from whom new active TB cases will arise. Understanding the spatio-temporal dynamics of host immune responses in LTBI granulomas is essential to designing effective post-exposur...

Descripción completa

Detalles Bibliográficos
Autores: Rao, Mangala|||0000-0002-0579-1097, Ippolito, Giuseppe|||0000-0002-1076-2979, Mfinanga, Sayoki, Ntoumi, Francine, Yeboah-Manu, Dorothy|||0000-0002-1663-6287, Vilaplana, Cristina|||0000-0002-2808-7270, Zumla, Alimuddin|||0000-0002-5111-5735, Maeurer, Markus|||0000-0002-8436-8077
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:223225
Acceso en línea:https://ddd.uab.cat/record/223225
https://dx.doi.org/urn:doi:10.1016/j.ijid.2019.02.035
Access Level:acceso abierto
Palabra clave:Granuloma
Host-directed therapies
Immune landscape
Latent tuberculosis infection
Mutations
Descripción
Sumario:Latent tuberculosis infection (LTBI) is established in over 90% of persons infected with Mycobacterium tuberculosis (Mtb), from whom new active TB cases will arise. Understanding the spatio-temporal dynamics of host immune responses in LTBI granulomas is essential to designing effective post-exposure therapies that inhibit progression to TB. Information arising from cancer studies and other modalities - where local chronic inflammation leads to immunopathology - can help provide insights into the biological pathways at play in LTBI granulomas. Translational studies using patient material as well as LTBI+ donor-derived tissue samples are instrumental in understanding the various components of granuloma dynamics, immunological landscapes therein and how this could help to identify therapeutic targets. Deep sequencing technologies may aid to decipher the genetic changes in lung granuloma and blood samples from LTBI+ individuals associated with progression to active TB disease. This may lead to advancement of development of targeted Host-Directed Therapies (HDTs) and their evaluation as adjunct TB therapies for improving treatment outcomes for LTBI and pulmonary TB.

Similares en LA Referencia